Omeros closes $68.3 million public stock offering

Omeros has closed its underwritten public offering with 3 million shares of its common stock being sold at $22.75 per share, according to a company press release.The company generated $63.6 million of net proceeds from the offering, which it intends to use for “general corporate purposes.” This includes research and development of its OMS721 programs, clinical trials, manufacturing costs and other costs that will assist the company in advancing its product candidates toward biologic license application and new drug application submissions.

Full Story →